US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Former Spain coach Del Bosque to head the commission overseeing beleaguered soccer federation
MADRID (AP) — Former Spain coach Vicente del Bosque will lead the Spanish government’s commission ov2024-05-01Explore Taiwan's Treasure Hill Artist Village
Once home to the military families, Treasure Hill Artist Village has become one of Taipei’s mo2024-05-01VOX POPULI: Time’s up for wallowing in nostalgia for the Showa Era
I once started writing “like a broken record” and stopped, realizing this could all be Greek to the2024-05-01NZ public service job cuts: what we know so far
Wellington's public sector workforce will take a hit. Photo: RNZ / Richard Tindiller2024-05-01Box office: ‘Challengers’ scores with $15 million in ticket sales
The sexy tennis drama “ Challengers ” won the box office this weekend with $15 million in ticket sal2024-05-01Three sons of Hamas leader Ismail Haniyeh killed in Israeli airstrike
Hamas leader Ismail Haniyeh. Photo: AFP2024-05-01
atest comment